Trial Profile
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 03 Sep 2020
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms FINNjA-DM
- 31 Aug 2020 Planned End Date changed from 1 Nov 2012 to 1 May 2013.
- 31 Aug 2020 Status changed from discontinued to withdrawn prior to enrolment.
- 23 May 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.